See more : C29 Metals Limited (C29.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Fresh Tracks Therapeutics, Inc. (FRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fresh Tracks Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sadbhav Engineering Limited (SADBHAV.NS) Income Statement Analysis – Financial Results
- Dinglong Culture Co., Ltd. (002502.SZ) Income Statement Analysis – Financial Results
- Metro Performance Glass Limited (MPP.AX) Income Statement Analysis – Financial Results
- Entera Bio Ltd. WT EXP 062723 (ENTXW) Income Statement Analysis – Financial Results
- Task Group Holdings Limited (TSK.NZ) Income Statement Analysis – Financial Results
Fresh Tracks Therapeutics, Inc. (FRTX)
About Fresh Tracks Therapeutics, Inc.
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.01M | 6.94M | 404.00K | 1.82M | 7.92M | 1.62M | 13.82M | 14.53M | 20.95M | 15.22M | 7.72M | 17.52M | 30.02M | 8.71M | 12.69M | 7.96M | 5.51M | 14.74M | 12.00M | 14.55M | 8.08M | 7.01M | 11.37M | 7.62M | 10.70M | 5.90M | 7.80M | 6.70M | 6.30M | 5.50M | 6.00M | 3.60M | 2.40M | 1.80M |
| Cost of Revenue | 0.00 | 14.04M | 28.23M | 11.22M | 20.21M | 1.44M | 6.48M | 6.29M | 10.93M | 10.82M | 12.70M | 0.00 | 10.27M | 11.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.20M | -1.00M | -900.00K | -900.00K | -600.00K | -500.00K | -500.00K | 5.70M | 4.00M | 3.00M | 2.20M |
| Gross Profit | 8.01M | -7.10M | -27.83M | -9.39M | -12.30M | 186.00K | 7.34M | 8.24M | 10.02M | 4.39M | -4.98M | 17.52M | 19.75M | -2.73M | 12.69M | 7.96M | 5.51M | 14.74M | 12.00M | 14.55M | 8.08M | 7.01M | 11.37M | 8.82M | 11.70M | 6.80M | 8.70M | 7.30M | 6.80M | 6.00M | 300.00K | -400.00K | -600.00K | -400.00K |
| Gross Profit Ratio | 100.00% | -102.26% | -6,887.87% | -515.59% | -155.32% | 11.47% | 53.12% | 56.71% | 47.84% | 28.87% | -64.52% | 100.00% | 65.80% | -31.28% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 115.75% | 109.35% | 115.25% | 111.54% | 108.96% | 107.94% | 109.09% | 5.00% | -11.11% | -25.00% | -22.22% |
| Research & Development | 3.18M | 14.04M | 28.23M | 11.22M | 20.21M | 12.33M | 14.39M | 10.36M | 11.06M | 11.47M | 14.56M | 17.34M | 17.98M | 19.69M | 23.45M | 25.53M | 22.93M | 18.51M | 17.77M | 31.18M | 26.78M | 26.37M | 22.07M | 18.51M | 15.30M | 12.10M | 11.90M | 11.30M | 9.00M | 8.30M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.18M | 14.43M | 12.42M | 11.58M | 12.17M | 8.94M | 12.81M | 13.35M | 19.29M | 20.38M | 24.51M | 23.61M | 0.00 | 8.80M | 7.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.44M | 6.48M | 6.29M | 10.93M | 10.82M | 12.70M | 13.06M | 0.00 | 0.00 | 10.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.18M | 14.43M | 12.42M | 11.58M | 12.17M | 8.94M | 12.81M | 13.35M | 19.29M | 20.38M | 24.51M | 23.61M | 9.60M | 8.80M | 17.82M | 19.77M | 22.84M | 22.64M | 19.88M | 8.51M | 6.92M | 8.06M | 6.52M | 5.27M | 4.40M | 3.60M | 3.70M | 3.20M | 2.90M | 2.60M | 2.00M | 1.40M | 1.10M | 800.00K |
| Other Expenses | 0.00 | 441.00K | 839.00K | 0.00 | 0.00 | -1.44M | -6.48M | -6.29M | -10.93M | -10.82M | -12.70M | -13.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 482.22K | 4.20M | 0.00 | 1.20M | 1.00M | 900.00K | 900.00K | 600.00K | 500.00K | 500.00K | 400.00K | 400.00K | 600.00K | 600.00K |
| Operating Expenses | 14.37M | 28.48M | 40.65M | 22.80M | 32.39M | 21.27M | 27.21M | 23.71M | 30.35M | 31.84M | 39.07M | 40.95M | 27.57M | 28.49M | 41.27M | 45.30M | 45.77M | 41.16M | 37.65M | 39.69M | 34.18M | 38.64M | 28.60M | 24.98M | 20.70M | 16.60M | 16.50M | 15.10M | 12.40M | 11.40M | 2.40M | 1.80M | 1.70M | 1.40M |
| Cost & Expenses | 14.37M | 28.48M | 40.65M | 22.80M | 32.39M | 21.27M | 27.21M | 23.71M | 30.35M | 31.84M | 39.07M | 40.95M | 37.84M | 39.93M | 41.27M | 45.30M | 45.77M | 41.16M | 37.65M | 39.69M | 34.18M | 38.64M | 28.60M | 23.78M | 19.70M | 15.70M | 15.60M | 14.50M | 11.90M | 10.90M | 8.10M | 5.80M | 4.70M | 3.60M |
| Interest Income | 0.00 | 9.00K | 69.00K | 63.00K | 1.94M | 61.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.83M | 2.21M | 2.07M | 3.98M | 8.29M | 9.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.00K | 9.00K | 69.00K | 0.00 | 2.10M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 21.00K | 96.00K | 272.00K | 533.00K | 795.00K | 412.82K | 288.25K | 296.58K | 204.60K | 0.00 | 200.00K | 0.00 | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 100.00K | 100.00K |
| Depreciation & Amortization | 41.00K | 30.00K | 22.00K | 10.00K | 28.00K | 49.00K | 793.00K | 1.12M | 1.16M | 1.66M | 2.21M | 1.98M | 2.30M | 2.81M | 2.63M | 2.87M | 3.26M | 3.28M | 3.59M | 3.64M | 3.54M | 2.74M | 1.88M | 1.20M | 1.00M | 900.00K | 900.00K | 600.00K | 500.00K | 500.00K | 400.00K | 400.00K | 600.00K | 600.00K |
| EBITDA | -5.65M | -21.06M | -39.38M | -20.90M | -24.47M | -19.50M | -12.59M | -8.06M | -8.25M | -14.96M | -29.14M | -21.11M | -5.32M | -28.41M | -25.93M | -34.48M | -37.00M | -23.13M | -22.06M | -21.51M | -22.56M | -28.89M | -15.35M | -14.96M | -8.00M | -8.90M | -6.90M | -7.20M | -5.10M | -4.90M | -1.70M | -1.80M | -1.70M | -1.20M |
| EBITDA Ratio | -70.55% | -303.80% | -9,961.39% | -1,151.26% | -309.06% | -1,420.35% | -99.95% | -64.56% | -40.15% | -110.14% | -407.70% | -136.81% | -27.85% | -326.10% | -204.85% | -439.20% | -752.21% | -180.97% | -183.76% | -147.86% | -273.30% | -352.37% | -135.02% | -196.31% | -74.77% | -191.53% | -119.23% | -149.25% | -107.94% | -110.91% | -43.33% | -58.33% | -75.00% | -77.78% |
| Operating Income | -6.36M | -21.53M | -40.24M | -20.98M | -24.47M | -19.65M | -13.39M | -9.18M | -9.40M | -16.63M | -31.35M | -23.43M | -7.82M | -31.22M | -28.59M | -37.34M | -40.26M | -26.42M | -25.65M | -25.14M | -26.10M | -31.63M | -17.23M | -16.16M | -9.00M | -9.80M | -7.80M | -7.80M | -5.60M | -5.40M | -2.10M | -2.20M | -2.30M | -1.80M |
| Operating Income Ratio | -79.44% | -310.15% | -9,961.39% | -1,151.26% | -309.06% | -1,211.22% | -96.87% | -63.15% | -44.89% | -109.26% | -406.22% | -133.76% | -26.06% | -358.34% | -225.34% | -469.37% | -730.44% | -179.22% | -213.70% | -172.86% | -323.12% | -451.36% | -151.59% | -212.06% | -84.11% | -166.10% | -100.00% | -116.42% | -88.89% | -98.18% | -35.00% | -61.11% | -95.83% | -100.00% |
| Total Other Income/Expenses | 666.00K | 432.00K | 770.00K | 63.00K | 591.00K | 3.39M | 426.00K | 204.00K | 166.00K | 134.00K | 114.00K | 534.00K | 539.00K | 830.00K | 28.00K | 468.00K | 4.46M | 3.54M | 0.00 | 0.00 | -481.56K | -4.20M | 0.00 | 0.00 | 0.00 | 2.40M | 2.40M | 2.80M | 1.70M | 1.20M | 900.00K | 300.00K | 100.00K | 200.00K |
| Income Before Tax | -5.69M | -21.10M | -39.47M | -20.91M | -23.88M | -16.25M | -12.96M | -8.97M | -9.24M | -16.49M | -31.24M | -22.90M | -7.28M | -30.39M | -28.56M | -36.88M | -35.80M | -22.88M | 0.00 | 0.00 | -26.59M | -35.83M | 0.00 | 0.00 | 0.00 | -7.40M | -5.40M | -5.00M | -3.90M | -4.20M | -1.20M | -1.90M | -2.20M | -1.60M |
| Income Before Tax Ratio | -71.12% | -303.93% | -9,770.79% | -1,147.80% | -301.59% | -1,002.10% | -93.78% | -61.75% | -44.10% | -108.38% | -404.74% | -130.71% | -24.26% | -348.81% | -225.10% | -463.49% | -649.46% | -155.20% | 0.00% | 0.00% | -329.09% | -511.30% | 0.00% | 0.00% | 0.00% | -125.42% | -69.23% | -74.63% | -61.90% | -76.36% | -20.00% | -52.78% | -91.67% | -88.89% |
| Income Tax Expense | 0.00 | -441.00K | 47.00K | -10.00K | 2.07M | 4.48M | -1.22M | -1.32M | -166.00K | -1.80M | -2.33M | -2.52M | -2.84M | 0.00 | -28.00K | -447.00K | -4.37M | -3.27M | -1.29M | -1.41M | -1.65M | -3.70M | -7.99M | -7.64M | -2.10M | -2.30M | -2.20M | -2.70M | -1.60M | -1.00M | -700.00K | -200.00K | 0.00 | -100.00K |
| Net Income | -5.69M | -20.66M | -39.52M | -20.90M | -25.95M | -16.25M | -12.96M | -8.97M | -9.24M | -16.49M | -31.24M | -22.90M | -7.28M | -30.39M | -28.56M | -36.90M | -35.89M | -23.15M | -24.36M | -23.73M | -24.45M | -27.93M | -9.24M | -8.52M | -6.90M | -7.50M | -5.60M | -5.10M | -4.00M | -4.40M | -1.40M | -2.00M | -2.30M | -1.70M |
| Net Income Ratio | -71.12% | -297.58% | -9,782.43% | -1,147.26% | -327.71% | -1,002.10% | -93.78% | -61.75% | -44.10% | -108.38% | -404.74% | -130.71% | -24.26% | -348.81% | -225.11% | -463.75% | -651.20% | -157.04% | -202.92% | -163.17% | -302.65% | -398.62% | -81.29% | -111.77% | -64.49% | -127.12% | -71.79% | -76.12% | -63.49% | -80.00% | -23.33% | -55.56% | -95.83% | -94.44% |
| EPS | -0.96 | -7.36 | -22.14 | -38.37 | -386.21 | -234.41 | -316.76 | -282.12 | -317.17 | -585.11 | -1.13K | -839.10 | -318.51 | -1.59K | -1.91K | -2.92K | -2.89K | -2.32K | -3.12K | -3.29K | -3.83K | -4.38K | -1.45K | -1.36K | -1.35K | -1.50K | -1.14K | -1.04K | -913.45 | -1.07K | -440.94 | -724.38 | -850.59 | -693.03 |
| EPS Diluted | -0.96 | -7.36 | -22.14 | -38.37 | -386.21 | -234.41 | -316.76 | -282.12 | -317.17 | -585.11 | -1.13K | -839.10 | -318.51 | -1.59K | -1.91K | -2.92K | -2.89K | -2.32K | -3.12K | -3.29K | -3.83K | -4.38K | -1.45K | -1.36K | -1.35K | -1.49K | -1.14K | -1.04K | -913.45 | -1.07K | -440.94 | -724.38 | -850.59 | -693.03 |
| Weighted Avg Shares Out | 5.91M | 2.81M | 1.78M | 544.76K | 67.18K | 69.34K | 40.91K | 31.81K | 29.13K | 28.19K | 27.57K | 27.29K | 22.87K | 19.07K | 14.95K | 12.65K | 12.44K | 9.98K | 7.80K | 7.20K | 6.38K | 6.37K | 6.36K | 6.25K | 5.12K | 5.02K | 4.92K | 4.88K | 4.38K | 4.11K | 3.18K | 2.76K | 2.70K | 2.45K |
| Weighted Avg Shares Out (Dil) | 5.91M | 2.81M | 1.78M | 544.76K | 67.18K | 69.34K | 40.91K | 31.81K | 29.13K | 28.19K | 27.57K | 27.29K | 22.87K | 19.07K | 14.95K | 12.65K | 12.44K | 9.98K | 7.80K | 7.20K | 6.38K | 6.37K | 6.36K | 6.25K | 5.12K | 5.04K | 4.93K | 4.89K | 4.38K | 4.11K | 3.18K | 2.76K | 2.70K | 2.45K |
BBI Stock Fell Over 20% Pre-Market: Why It Happened
The stock price of Brickell Biotech Inc (NASDAQ: BBI) fell by over 20% pre-market. This is why it happened.
Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million
BOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (the “Company” or “Brickell”), clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that, due to...
Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock
BOULDER, Colo., July 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” or the “Company”), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it...
Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Topline results for Phase 3 Pivotal Cardigan I and Cardigan II studies expected in Q4 2021 Topline results for Phase 3 Pivotal Cardigan I and Cardigan II studies expected in Q4 2021
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q1 2021 Results - Earnings Call Transcript
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q1 2021 Results - Earnings Call Transcript
Brickell (BBI) Reports Q1 Loss, Lags Revenue Estimates
Brickell (BBI) delivered earnings and revenue surprises of -25.00% and -83.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Brickell Biotech: Q1 Earnings Insights
Shares of Brickell Biotech (NASDAQ:BBI) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 66.67% year over year to ($0.15), which missed the estimate of ($0.11).
Will Brickell (BBI) Report Negative Earnings Next Week? What You Should Know
Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021
BOULDER, Colo., April 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its...
Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Phase 3 Pivotal Cardigan II study exceeds 50% enrollment - - - Topline results for Phase 3 Pivotal Cardigan I and Cardigan II clinical studies expected in Q4 2021
Source: https://incomestatements.info
Category: Stock Reports